OTCMKTS:BIOQ Bioqual Q4 2025 Earnings Report $33.00 0.00 (0.00%) As of 09/25/2026 ProfileEarnings History Bioqual EPS ResultsActual EPS-$0.11Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioqual Revenue ResultsActual Revenue$11.67 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioqual Announcement DetailsQuarterQ4 2025Date9/19/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Bioqual Earnings HeadlinesBIOQUAL Presents Financial Results for Fiscal Year 2026September 22, 2026 | businesswire.comBioqual (OTCMKTS:BIOQ) Releases Earnings ResultsSeptember 22, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026April 21, 2026 | businesswire.comBIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026January 22, 2026 | businesswire.comPETA files complaint over Mississippi monkey truck crash, citing animal welfare violationsNovember 7, 2025 | msn.comSee More Bioqual Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email. Email Address About BioqualBioqual (OTCMKTS:BIOQ), Inc. is a contract research organization that provides preclinical biomedical research services to pharmaceutical, biotechnology and government customers. The company specializes in infectious disease research and uses laboratory and animal models to support the development and evaluation of vaccines, therapeutics and diagnostic products. Its services have included studies involving HIV, hepatitis, influenza, COVID-19 and other infectious diseases, as well as immunology, pharmacology and toxicology research. Bioqual also provides research support using nonhuman primate and other animal models, along with laboratory testing and related scientific services. Based in the United States, Bioqual has historically served customers in the pharmaceutical, biotechnology and public-sector research communities. Publicly available information about its current leadership and operations is limited.View Bioqual ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
